Invitation to Attend the Annual General Meeting of Tripep AB
24 févr. 2004 05h32 HE
|
Tripep
HUDDINGE, Sweden, Feb. 24, 2004 (PRIMEZONE) -- The Annual General Meeting of Tripep AB will be held on 25 March 2004 at 6 p.m. at the Kilsalen Room, Berns Conference Facility, Berzelii Park,...
Tripep Disclosure notice
04 févr. 2004 05h58 HE
|
Tripep
HUDDINGE, Sweden, Feb. 04, 2004 (PRIMEZONE) -- Dormant Properties AB, a company controlled by Tripep's Chairman of the Board, Rolf L. Nordstrom, acquired a total of 86,000 Tripep AB shares on 3...
Tripep Year-end report 2003
30 janv. 2004 05h14 HE
|
Tripep
HUDDINGE, Sweden, Jan. 30, 2004 (PRIMEZONE) -- Tripep AB (publ):
- Loss after tax for the full year 2003: SEK -13.0 million (SEK - 42.5 m). Research and development costs for the full year 2003:...
Tripep secures U.S. patent for new application for antiviral substance ribavirin
21 janv. 2004 05h47 HE
|
Tripep
HUDDINGE, Sweden, Jan. 21, 2004 (PRIMEZONE) -- Tripep has secured a new patent, granted in the U.S. today. The patent states the discovery that ribavirin can be used to reinforce the immune defence...
Tripep is granted loan remission by Industrifonden
19 déc. 2003 07h15 HE
|
Tripep
HUDDINGE, Sweden, Dec. 19, 2003 (PRIMEZONE) -- Tripep has received remission of half the loan of SEK 20 million from Industrifonden. As announced earlier, Tripep had applied for remission of the SEK...
Tripep AB 's Disclosure notice
10 nov. 2003 07h45 HE
|
Tripep
HUDDINGE, Sweden, Nov. 10, 2003 (PRIMEZONE) -- Dormant Properties AB, a company controlled by Tripep's Chairman of the Board, Rolf L. Nordstrom, acquired a total of 269,000 Tripep AB shares on 4 and...
Clarification concerning alfaHGA, Tripep's new candidate drug against HIV
30 oct. 2003 10h06 HE
|
Tripep
HUDDINGE, Sweden, Oct. 30, 2003 (PRIMEZONE) -- Tripep has identified the active component of GPG Clarification concerning alfaHGA, Tripep's new candidate drug against HIV.
Yesterday, the O-listed...
Tripep: Alpha HGA, New Candidate Drug Against HIV
29 oct. 2003 04h26 HE
|
Tripep
HUDDINGE, Sweden, Oct. 29, 2003 (PRIMEZONE) -- This letter concerns the dissemination of the press release alpha HGA, new candidate drug against HIV from TRIPEP earlier this morning at 07:30...
Tripep Interim Report, January -- September 2003
27 oct. 2003 09h06 HE
|
Tripep
HUDDINGE, Sweden, Oct. 27, 2003 (PRIMEZONE) -- Tripep AB (publ) - Interim Report, January - September 2003
. Result after tax: -SEK 17.2 million (-SEK 38.9 m).
Research and development...
Tripep Interim report January -- June 2003
01 sept. 2003 05h23 HE
|
Tripep
HUDDINGE, Sweden, Sept. 01, 2003 (PRIMEZONE) -- Tripep AB (publ):
- Result after tax: -SEK 11.9 million (-SEK 32.5 m). Research and development costs: SEK 6.6 million (SEK 9.4 m). The company has...